A nticoagulation with warfarin is widely used to prevent stroke and other thromboembolic events. Efficacy and safety of vitamin K antagonists, such as warfarin, are dependent on the quality of anticoagulation control as reflected by the average time each patient spends in the therapeutic range (TTR). With a high TTR, thromboembolic and bleeding risks are reduced. [1] [2] [3] [4] [5] [6] As such, TTR is considered a major factor in reducing adverse events in anticoagulated patients treated with warfarin. However,
the effect of TTR on warfarin-treated patients with heart failure (HF) in sinus rhythm (SR) is not known, and no previous study has assessed this issue. This question is particularly important when considering the potential of evaluating the role of newer, non-vitamin K antagonist oral anticoagulants in preventing adverse events in patients with HF. The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial was the largest double-blind randomized study of HF patients in SR treated with warfarin or aspirin. 7 It showed that although ischemic stroke was reduced by the use of warfarin, the primary end point of stroke (ischemic and hemorrhagic) or death combined did not differ between the 2 arms. Warfarin use was also associated with increased bleeding. We hypothesized that outcome events and bleeding in those receiving warfarin may have been influenced by the level of TTR achieved. As such, in the current ancillary analysis, we tested this hypothesis by examining the relationship of TTR and event rates. In addition, we explored the major hemorrhage rate in relation to TTR in patients with HF. As far as we are aware, this is the first study to assess warfarin effectiveness and bleeding rate classified by TTR in patients with HF in SR.
Methods

Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial
This analysis used information obtained from the doubleblind WARCEF trial (http://www.ClinicalTrials.gov; number, NCT00041938), in which patients with left ventricular EF ≤35% in SR were randomly assigned to warfarin (target international normalized ratio [INR)], 2.75; with an acceptable INR range of 2.0-3.5) or aspirin (325 mg per day). The design has been previously reported. 7 The primary efficacy outcome was the time to the first occurrence of stroke (ischemic or hemorrhagic) or death. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, retinal hemorrhage, any other bleeding with >2 g hemoglobin decline in 48 hours, those requiring 2 units or more of transfusion, or requiring hospitalization or surgical intervention. This study was approved by Institutional Review Boards at the coordinating centers for all sites, and all subjects provided informed consent.
Analysis
To assess TTR, daily INRs were imputed. We assumed that any change between 2 consecutive INR measurements takes place linearly for a 5-day period. For the time period between 2 consecutive INR measurements, we imputed INR backward using the INR value of the second measurement till 5 days after the first measurement. Then, we imputed the first 5 days using linear interpolation of these 2 INR values. 8 A 6-week initial titration phase is allowed when calculating TTR. At each time point, TTR for each patient is the up-to-date percentage of time on study medication from the seventh week for which the patient was in the TTR (INR of 2-3.5). The final TTR for each patient is the patient's TTR at the end of follow-up. Seventy-five warfarin-treated patients either had a follow-up time of <6 weeks or were on interruption of therapy after 6 weeks, and thus missing TTR throughout the study. These patients were excluded from the analyses. To allow for a fair comparison, 13 aspirin-treated patients with a follow-up time of <6 weeks were also excluded, giving a total sample of 2217 patients.
We divided warfarin-treated patients into 2 groups, the high-TTR group (final TTR≥60%) and the low TTR (final TTR<60%) group; the cut point of 60% yields a similar sample size in each group. Clinical and laboratory variables, as well as adverse events, were compared among these 2 groups and aspirin-treated patients using an ANOVA F-test for continuous variables, χ 2 test for categorical variables, and log-rank test for time-to-event outcomes.
Cox models in which TTR was treated as a time-dependent covariate were used to assess the effect of TTR on the primary outcome, on death alone, on ischemic stroke alone, and on major hemorrhage among all warfarin-treated patients. Net clinical benefit was assessed by combining the primary outcome and major hemorrhage.
We also compared the risk of the primary outcome among the high-TTR group (TTR≥60%), the low-TTR group (TTR<60%), and the aspirin-treated patients using a Cox model, in which the TTR groups were time-dependent, that is, they changed over time based on the value of the up-to-date TTR value for each patient.
All the analyses were stratified by continent, taking advantage of the fact that randomization in WARCEF was stratified by site and therefore by continent. To address the possibility that better TTR may be a proxy for better baseline health or better health awareness and access to medical care, we considered all baseline characteristics listed in Table 1 and adjusted the above analyses for variables that were significantly associated with each outcome by using stepwise forward-backward selection, with entry and removal criteria of P=0.05. P values for the regression coefficients and 95% confidence interval were calculated based on the Wald test. Missing values were imputed using means for continuous variables and modal values for categorical variables. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC).
Results
Of the 2217 patients, 1067 were randomized to warfarin and 1150 patients to aspirin. Overall median (interquartile range) follow-up was 3.6 (2.0-5.0) years. Descriptive statistics for patient variables and adverse events are shown in Table 1 . Overall, 71 461 INRs were analyzed in 5 laboratories that represented geographic locations of the study sites (North America, South America, and 3 locations in Europe). The mean (±SD) final TTR per patient was 57% (±28.5%) for warfarin-treated patients, lower than the overall proportion of TTR reported in the primary WARCEF article because patients with shorter times on warfarin had lower TTRs. 7 When patients were not in the TTR, on average, more time was spent below the TTR (32.4±28.9%) than above (10.5±12.9%).
Results showing the effect of time-dependent TTR on timeto-event outcomes are presented in Table 2 . In 3 of the 5 outcomes of interest, the event risk declined significantly as TTR increased. For every 10% increase in TTR, the adjusted hazard ratio (aHR) for the primary outcome was 0.92 (P<0.001) and the aHR for death was 0.93 (P=0.001). For ischemic stroke alone, the aHR of event was 0.88 for every 10% increase in TTR but did not reach the significance (P=0.082). Similarly, for major hemorrhage, the aHR of event was 0.93 (P=0.109). For net benefit of warfarin, which combines the primary composite event and major hemorrhage, the aHR was 0.91 for every 10% increase in TTR (P<0.001). We also tested for the effect of TTR when it was limited to 2 to 3 as a sensitivity analysis and observed similar results (data not shown).
A time-dependent comparison of primary outcome risk among the high TTR, low TTR, and aspirin-treated groups is presented in Table 3 . Those with high TTRs at any time were at less risk of an event than both those with lower TTRs at any time (aHR=0.74; P=0.015) and those in the aspirin-treated group (aHR=0.76; P=0.010), whereas the low-TTR group experienced similar risk as the aspirin group (aHR=1.03; P=0.790).
Discussion
In this study, we show for the first time that in patients with HF in SR, increasing TTR is associated with better outcomes and improved net clinical benefit. Patients with high TTR fared better than patients with low TTR and those receiving aspirin. On the other hand, patients with low TTR tended to do similarly compared with patients receiving aspirin, implying that high quality anticoagulation with warfarin or potentially the use of newer oral anticoagulants may be better than aspirin in preventing adverse outcomes.
In patients with atrial fibrillation (AF), the efficacy of vitamin K antagonists, such as warfarin, in preventing adverse events depends on the individual patient's TTR. [1] [2] [3] [4] A higher TTR is associated with a lower event probability. It is also shown that in other clinical situations in which anticoagulation is indicated, the event rate declines as TTR increases. 5, 6 In our analysis of WARCEF data, the lower event rates with high TTR were observed for primary event, death alone, and for net clinical benefit. There was a trend toward better stroke outcomes with high TTR, but this did not reach statistical significance. Patients with high TTR also did better compared with aspirin-treated patients. Although WARCEF lacked a placebo group, the increasing effectiveness of warfarin as TTR increases is consistent with a potential benefit of warfarin in HF if the quality of anticoagulation control was good. Patients with HF, particularly those with reduced EF, are at increased risk for cardiovascular death. 9 It has been shown that cardiac events may be because of microembolization. 10 It is possible that such events were prevented in our study by the use of warfarin, thus leading to lower rate of death. It is also known that patients with HF tend to develop AF. 11 As such, it is possible that transient AF may have developed in our patients, as has been noted in patients with unknown cause of stroke, and that embolic events from occult AF may have been prevented by effective anticoagulation. 12, 13 In addition, because there was a trend toward decreasing bleeding rate as TTR increased, this led to increasing net benefit as TTR increased. Of note, this benefit occurred in a nearly linear fashion without any particular threshold value. The role of newer oral anticoagulants in preventing adverse events in patients with HF without AF remains undefined. Although WARCEF clearly demonstrated a reduction in ischemic stroke with use of warfarin compared with aspirin, this was counterbalanced by the increase in bleeding episodes. 7 WARCEF did not demonstrate a reduction in death for warfarintreated group compared with aspirin-treated group. However, because continued warfarin use is not always adhered to in warfarin-treated patients often because of required repeated blood checks, use of non-vitamin K oral anticoagulants, which does not require INR checks, may improve quality of anticoagulation and thus improve outcomes. 14 Because mortality is reduced as TTR increases, it is possible that the use of newer oral anticoagulants with their more consistent therapeutic anticoagulation effect may reduce deaths. Several clinical trials of newer oral anticoagulants in patients with AF analyzed their effectiveness in HF. [15] [16] [17] These studies showed that the benefit was at least similar (and sometimes better) when compared with warfarin. The stroke rate among AF patients with reduced left ventricular EF in Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial was significantly lower compared with warfarin-treated patients. 17 Furthermore, because the major bleeding rates are generally lower with newer oral anticoagulants than with warfarin, these agents may deliver a positive net clinical benefit. 18, 19 A major limitation of this study is that it is not clear from our analysis how factors other than TTR influenced the beneficial effect associated with higher TTR beyond baseline variables. Such factors as geographical location, better care for patients, adherence to HF medical therapy, and regularly scheduled test are associated with better TTR, and many of these factors will improve outcomes. [20] [21] [22] [23] In addition, because there was no placebo group, whether patients treated with warfarin would do better than those without either warfarin or aspirin treatment remains unknown. As such, a direct cause-effect relationship between higher TTR and better outcomes is not shown in our current analysis. However, better outcome as TTR increases, and high-TTR group having lower event rate compared with the low TTR or the aspirin-treated group, is consistent with a therapeutic effect of anticoagulants.
In conclusion, increasing TTR was associated with better outcomes in the WARCEF trial, with a reduction in death and improved net clinical benefit in patients with HF in SR. We suggest that patients with HF in SR in whom good quality anticoagulation can be achieved may benefit from the use of anticoagulants. 
